HK StockDetailed Quotes

Provided by Tiger Fintech (Singapore) Pte. Ltd.

Nonprofit Pharmaceutical Companies

627.079

+14.1902.32%

Number of Gainers:23

Number of Losers:6

Number of Flat:5

PE:- -

High:631.140

Open:615.021

Low:615.021

Close:612.889

Volume:104.37M

Turnover:2.79B

Market Cap:385.64B

Float Cap:345.61B

Loading ...

InnoCare Pharma (SEHK:9969): Evaluating Valuation After Sales Growth and Pipeline Advances Spark Market Interest

Simply Wall St.

InnoCare Pharma Logs Over 34 Million Yuan in Q3 Loss

MT Newswires Live

Huimin Insurance Updates: Multi-tiered Premiums Introduced, Shantou Links with Innovative Drug Directory

Fuerjia: No Current Plans to Establish Medical Device R&D Subsidiary in Hainan

Daxing Airport Economic Zone Global Investment Partner Conference Unveils Major Collaboration Opportunities

Executive Director Yang Jianxin Increases Stake in CStone Pharma-B (02616) by 100,000 Shares at Average Price of HK$5.35 per Share

Second Wave of Biotech Rally Kicks Off? HK Connect Biotech ETF Surges! Shanghai Index Hits Decade High, HK Tech ETF (159131) Debuts Strongly

CanSino Biologics Begins Phase 1 Trial of Tuberculosis Booster Vaccine in Indonesia

MT Newswires Live

JACOBIO-B (01167) Spends HK$498,300 to Repurchase 72,000 Shares on November 13

HBM HOLDINGS-B (02142) Repurchases 200,000 Shares for HK$2.7 Million on November 13

HBM Holdings Repurchases 200,000 Shares at HKD 13.24–13.67, Files Disclosure to HKEX

CARSGEN-B (02171) Plans to Repurchase Up to Approximately 25.46 Million Shares; Major Shareholder Increases Holdings by 100,000 Shares

Innocare Pharma Limited (688428.SH) Reports Q3 Results with Net Loss of 64.41 Million Yuan

CITIC Securities: Rates AKESO (09926) as "Buy" on Strong Efficacy and Broad Market Potential of Innovative Drugs

IPO Preview: Can Haina Pharma's "CXO + Proprietary Pipeline" Model Shine in Hong Kong?

Venus Medtech Shareholders to Vote on Proposed Sale of Industrial Park Property on Nov. 28

MT Newswires Live

HK Stock Movement | GENFLEET-B (02595) Surges Over 8% in Late Trading as GFH375 Tablets Enter Phase III Clinical Trial for Metastatic Pancreatic Cancer

Haisco Pharmaceutical (002653.SZ) Receives Approval for New Indication of Innovative Drug HSK39297 Tablets in Clinical Trials

Ascentage Pharma (SEHK:6855): Evaluating Valuation After ASH Meeting Spotlights Pipeline Progress

Simply Wall St.

IPO Preview | Weijian Pharma: Doubling H1 2025 Revenue Ahead of Listing

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www-web.itiger.com/stock/BK1574/news"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental","symbol":"BK1574","isAnalysisPage":false},"__swrFallback__":{"@#url:\"https://hq.skytigris.cn/stock_info/detail/global\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"BK1574\",,,,,undefined,":{"symbol":"BK1574","market":"HK","secType":"PLATE","nameCN":"Nonprofit Pharmaceutical Companies","latestPrice":627.0787,"timestamp":1763021314092,"preClose":612.88885,"halted":0,"volume":104373100,"delay":0,"changeRate":0.023152,"floatShares":0,"shares":0,"eps":0,"marketStatus":"Not Yet Opened","change":14.189819,"latestTime":"11-13 16:00:00","open":615.02124,"high":631.1397,"low":615.02124,"amount":2792399983,"amplitude":0.026299,"askPrice":0,"askSize":0,"bidPrice":0,"bidSize":0,"shortable":3,"etf":0,"tradingStatus":0,"nextMarketStatus":{"tag":"Open","tradingStatus":2,"beginTime":1763083800000},"marketStatusCode":0,"adr":0,"adjPreClose":0,"openAndCloseTimeList":[[1762997400000,1763006400000],[1763010000000,1763020800000]],"pbRate":5.242517,"peRate":-43.274162,"turnoverRate":0.003801,"increases":23,"decrements":7,"flats":3,"marketCap":385644539840,"floatMarketCap":345608044416},"@#url:\"https://hq.skytigris.cn/stock_info/fundamental/all\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"BK1574\",,,,,undefined,":{"symbol":"BK1574","high":631.1397,"amplitude":0.026299,"preClose":612.88885,"low":615.02124,"pbRate":"5.242517","latestPrice":627.0787,"volume":104373100,"delay":0,"open":615.02124,"prevYearClose":331.1933,"prevWeekClose":587.579,"prevMonthClose":618.706,"prevQuarterClose":752.859,"fiveDayClose":608.991,"twentyDayClose":659.471,"sixtyDayClose":840.007,"secType":"PLATE","market":"HK","turnoverRate":0.003801,"peRate":-43.274162,"marketCap":385644539840,"floatMarketCap":345608044416,"timestamp":1763021314092,"nameCN":"Nonprofit Pharmaceutical Companies"},"@#url:\"https://hq.skytigris.cn/api/global/plate/up_down\",method:\"POST\",data:#delay:false,bkCodes:@\"BK1574\",,,,undefined,":{"bkCode":"BK1574","up":23,"down":6,"flat":5},"$inf$@#url:\"https://stock-news.skytigris.cn/v2/news/list\",params:#symbols:\"BK1574\",pageSize:20,pageCount:1,lang_content:\"en\",edition:\"fundamental\",,,undefined,":[{"items":[{"id":"2583651849","title":"InnoCare Pharma (SEHK:9969): Evaluating Valuation After Sales Growth and Pipeline Advances Spark Market Interest","url":"https://stock-news.laohu8.com/highlight/detail?id=2583651849","media":"Simply Wall St.","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2583651849?lang=en_us&edition=fundamental","pubTime":"2025-11-14 01:17","pubTimestamp":1763054273,"startTime":"0","endTime":"0","summary":"InnoCare Pharma (SEHK:9969) just reported higher sales and a smaller net loss for the first nine months of 2025, while also advancing key drug candidates in its clinical pipeline. This combination is catching investor attention.\nSee our latest analysis for InnoCare Pharma.\nMomentum has returned in a big way for InnoCare Pharma, with its share price rallying 5.08% over the past week and boasting a striking year-to-date gain of 165.38%. Even after a pullback in the last quarter, the total...","market":"hk","thumbnail":"https://images.simplywall.st/asset/industry/6111000-choice2-main-header/1585186599552","type":0,"news_type":0,"thumbnails":["https://images.simplywall.st/asset/industry/6111000-choice2-main-header/1585186599552"],"rights":{"source":"simplywall_highlight","url":"https://simplywall.st/stocks/hk/pharmaceuticals-biotech/hkg-9969/innocare-pharma-shares/news/innocare-pharma-sehk9969-evaluating-valuation-after-sales-gr","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://simplywall.st/stocks/hk/pharmaceuticals-biotech/hkg-9969/innocare-pharma-shares/news/innocare-pharma-sehk9969-evaluating-valuation-after-sales-gr","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"simplywall_highlight","symbols":["BK1574","09969","BK1161"],"gpt_icon":0},{"id":"2583593535","title":"InnoCare Pharma Logs Over 34 Million Yuan in Q3 Loss","url":"https://stock-news.laohu8.com/highlight/detail?id=2583593535","media":"MT Newswires Live","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2583593535?lang=en_us&edition=fundamental","pubTime":"2025-11-13 21:30","pubTimestamp":1763040603,"startTime":"0","endTime":"0","summary":"InnoCare Pharma  recorded an attributable loss of 34.3 million yuan in the third quarter of 2025, a Thursday Hong Kong bourse filing said.Loss per share for the three months stood at 0.02 yuan, with operating revenue rising 38% to 383.9 million yuan.The higher revenue was due to an increase in the sales revenue of core product orelabrutinib, as well as the upfront payment under an exclusive license agreement with Prolium Bioscience.For the nine months ended Sept. 30, attributable loss reached 64.4 million yuan, while operating revenue surged 60% to 1.12 billion yuan.","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["BK1574","BK0239","09969","BK1161","688428"],"gpt_icon":0},{"id":"1175522789","title":"Huimin Insurance Updates: Multi-tiered Premiums Introduced, Shantou Links with Innovative Drug Directory","url":"https://stock-news.laohu8.com/highlight/detail?id=1175522789","media":"Deep News","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1175522789?lang=en_us&edition=fundamental","pubTime":"2025-11-13 20:50","pubTimestamp":1763038240,"startTime":"0","endTime":"0","summary":"Beyond oncology and rare disease medications, treatments for chronic diseases, mental health conditions, out-of-hospital drugs, overseas medications, and original patented drugs are now covered in...","market":"nz","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK1161","06978","BK1574","159992"],"gpt_icon":0},{"id":"1161220888","title":"Fuerjia: No Current Plans to Establish Medical Device R&D Subsidiary in Hainan","url":"https://stock-news.laohu8.com/highlight/detail?id=1161220888","media":"Deep News","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1161220888?lang=en_us&edition=fundamental","pubTime":"2025-11-13 20:20","pubTimestamp":1763036434,"startTime":"0","endTime":"0","summary":"Harbin Fuerjia Technology Co., Ltd. (301371) stated on November 13 via an investor interaction platform that the company currently has no plans to establish a medical device research and development subsidiary in Hainan.","market":"fut","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["09996","BK1222","BK1574","159883","301371","09997","BK1100","BK0229","BK1583"],"gpt_icon":0},{"id":"1106791120","title":"Daxing Airport Economic Zone Global Investment Partner Conference Unveils Major Collaboration Opportunities","url":"https://stock-news.laohu8.com/highlight/detail?id=1106791120","media":"Deep News","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1106791120?lang=en_us&edition=fundamental","pubTime":"2025-11-13 20:01","pubTimestamp":1763035268,"startTime":"0","endTime":"0","summary":"Gathering momentum at the new national gateway, leading the way to a new future. On November 12, the 2025 Fifth Daxing Airport Economic Zone Global Investment Partner Conference, themed \"Gathering...","market":"nz","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK1515","BK1161","09939","BK1574"],"gpt_icon":0},{"id":"1132160958","title":"Executive Director Yang Jianxin Increases Stake in CStone Pharma-B (02616) by 100,000 Shares at Average Price of HK$5.35 per Share","url":"https://stock-news.laohu8.com/highlight/detail?id=1132160958","media":"Stock News","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1132160958?lang=en_us&edition=fundamental","pubTime":"2025-11-13 20:00","pubTimestamp":1763035229,"startTime":"0","endTime":"0","summary":"According to the latest disclosure from the Hong Kong Stock Exchange, on November 11, Executive Director Yang Jianxin purchased an additional 100,000 shares of CStone Pharma-B (02616) at an average...","market":"nz","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK1574","BK1161","02616"],"gpt_icon":0},{"id":"1119549035","title":"Second Wave of Biotech Rally Kicks Off? HK Connect Biotech ETF Surges! Shanghai Index Hits Decade High, HK Tech ETF (159131) Debuts Strongly","url":"https://stock-news.laohu8.com/highlight/detail?id=1119549035","media":"Deep News","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1119549035?lang=en_us&edition=fundamental","pubTime":"2025-11-13 19:41","pubTimestamp":1763034061,"startTime":"0","endTime":"0","summary":"On November 13, China's A-share market saw a broad rally, with the Shanghai Composite Index hitting a decade-high. The combined trading volume of Shanghai and Shenzhen exchanges exceeded 2 trillion...","market":"other","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK1574","515890","562560","000688.SH","512880","159967","000001.SH","000905.SH","399006","BK1161","159131","512510","159982","399001","159992","520880","510880","000300.SH","510300","06978"],"gpt_icon":0},{"id":"2583756199","title":"CanSino Biologics Begins Phase 1 Trial of Tuberculosis Booster Vaccine in Indonesia","url":"https://stock-news.laohu8.com/highlight/detail?id=2583756199","media":"MT Newswires Live","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2583756199?lang=en_us&edition=fundamental","pubTime":"2025-11-13 19:35","pubTimestamp":1763033737,"startTime":"0","endTime":"0","summary":"CanSino Biologics  initiated the phase 1 clinical trial of its inhaled tuberculosis vaccine in Indonesia recently and the first patient has been enrolled, a Thursday Hong Kong bourse filing said.The phase Ia and Ib trials for the vaccine were completed in Canada, with data demonstrating its safety and its effectiveness as a Bacillus Calmette-Guerin booster vaccine.Bacillus Calmette-Guerin is reportedly the only available tuberculosis vaccine in the world currently.","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["BK1161","06185","BK1574","BK1515","BK1191"],"gpt_icon":0},{"id":"1114130827","title":"JACOBIO-B (01167) Spends HK$498,300 to Repurchase 72,000 Shares on November 13","url":"https://stock-news.laohu8.com/highlight/detail?id=1114130827","media":"Stock News","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1114130827?lang=en_us&edition=fundamental","pubTime":"2025-11-13 19:30","pubTimestamp":1763033409,"startTime":"0","endTime":"0","summary":"JACOBIO-B (01167) announced that it repurchased 72,000 shares for HK$498,300 on November 13, 2025.","market":"other","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK1574","01167","BK1161"],"gpt_icon":0},{"id":"1188186555","title":"HBM HOLDINGS-B (02142) Repurchases 200,000 Shares for HK$2.7 Million on November 13","url":"https://stock-news.laohu8.com/highlight/detail?id=1188186555","media":"Stock News","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1188186555?lang=en_us&edition=fundamental","pubTime":"2025-11-13 19:06","pubTimestamp":1763031971,"startTime":"0","endTime":"0","summary":"HBM HOLDINGS-B (02142) announced that on November 13, 2025, the company repurchased 200,000 shares at a price range of HK$13.24 to HK$13.67 per share, totaling approximately HK$2.7 million.","market":"sg","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["02142","BK1574","BK1583","BK1161"],"gpt_icon":0},{"id":"2583683569","title":"HBM Holdings Repurchases 200,000 Shares at HKD 13.24–13.67, Files Disclosure to HKEX","url":"https://stock-news.laohu8.com/highlight/detail?id=2583683569","media":"Reuters","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2583683569?lang=en_us&edition=fundamental","pubTime":"2025-11-13 19:05","pubTimestamp":1763031930,"startTime":"0","endTime":"0","summary":"HBM Holdings Ltd. has filed a Next Day Disclosure Return to the Hong Kong Stock Exchange, reporting the repurchase of 200,000 shares at a total aggregate price of HKD 2,701,070. The repurchased shares are being held as treasury shares.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. HBM Holdings Ltd. published the original content used to generate this news brief on November 13, 2025, and is solely responsible for the information contained therein.","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251113:nNDLbwP8hd:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["02142","BK1583","BK1574","BK1161"],"gpt_icon":0},{"id":"1184989182","title":"CARSGEN-B (02171) Plans to Repurchase Up to Approximately 25.46 Million Shares; Major Shareholder Increases Holdings by 100,000 Shares","url":"https://stock-news.laohu8.com/highlight/detail?id=1184989182","media":"Stock News","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1184989182?lang=en_us&edition=fundamental","pubTime":"2025-11-13 18:10","pubTimestamp":1763028625,"startTime":"0","endTime":"0","summary":"CARSGEN-B (02171) announced an update to its share repurchase plan, approved by the board of directors, to buy back up to 25,461,295 shares in the open market over the next 50 Hong Kong trading days...","market":"other","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["02171","BK1585","BK1574","BK1161","BK1587"],"gpt_icon":0},{"id":"1102963016","title":"Innocare Pharma Limited (688428.SH) Reports Q3 Results with Net Loss of 64.41 Million Yuan","url":"https://stock-news.laohu8.com/highlight/detail?id=1102963016","media":"Stock News","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1102963016?lang=en_us&edition=fundamental","pubTime":"2025-11-13 17:16","pubTimestamp":1763025391,"startTime":"0","endTime":"0","summary":"Innocare Pharma Limited (688428.SH) released its third-quarter financial report for 2025, showing revenue of 1.115 billion yuan for the first nine months, a year-on-year increase of 59.85%. However,...","market":"nz","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-2","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK1574","BK0239","09969","688428","BK1161"],"gpt_icon":0},{"id":"1151848502","title":"CITIC Securities: Rates AKESO (09926) as \"Buy\" on Strong Efficacy and Broad Market Potential of Innovative Drugs","url":"https://stock-news.laohu8.com/highlight/detail?id=1151848502","media":"Stock News","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1151848502?lang=en_us&edition=fundamental","pubTime":"2025-11-13 16:50","pubTimestamp":1763023857,"startTime":"0","endTime":"0","summary":"CITIC Securities released a research report highlighting AKESO's (09926) robust R&D pipeline, with multiple investigational products and indications nearing approval. The company continues to expand...","market":"sh","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK1161","LU2399975544.HKD","LU0417516571.SGD","LU2476274720.SGD","LU0348767384.USD","09926","LU2488822045.USD","LU2778985437.USD","LU0417516738.SGD","LU1794554557.SGD","LU1720050803.USD","LU0348825331.USD","LU0348766576.USD","06978","LU0348783233.USD","BK1574","LU1961090484.USD","LU2476274308.USD","159992","IE00B5MMRT66.SGD","IE00BPRC5H50.USD","IE00B543WZ88.USD","LU0561508036.HKD","LU0348735423.USD","LU0348827113.USD","LU0540923850.HKD","LU0417516902.SGD","LU0634319403.HKD","LU0348784397.USD"],"gpt_icon":0},{"id":"1173746546","title":"IPO Preview: Can Haina Pharma's \"CXO + Proprietary Pipeline\" Model Shine in Hong Kong?","url":"https://stock-news.laohu8.com/highlight/detail?id=1173746546","media":"Stock News","labels":["preview"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1173746546?lang=en_us&edition=fundamental","pubTime":"2025-11-13 16:30","pubTimestamp":1763022626,"startTime":"0","endTime":"0","summary":"Nanjing Haina Pharmaceutical Technology Co., Ltd. (Haina Pharma) has submitted its IPO application to the Hong Kong Stock Exchange, with China International Capital Corporation (CICC) as its sole...","market":"sg","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"preview","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK1515","09939","BK1161","CXO","159938","BK1574"],"gpt_icon":0},{"id":"2583082551","title":"Venus Medtech Shareholders to Vote on Proposed Sale of Industrial Park Property on Nov. 28","url":"https://stock-news.laohu8.com/highlight/detail?id=2583082551","media":"MT Newswires Live","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2583082551?lang=en_us&edition=fundamental","pubTime":"2025-11-13 16:11","pubTimestamp":1763021509,"startTime":"0","endTime":"0","summary":"Shareholders of Venus Medtech  will meet Nov. 28 to vote on the proposed sale of certain property and land use rights related to the Qiming Healthcare Life Science Industrial Park in Hangzhou, a Wednesday Hong Kong bourse filing said.Shares of the medical device maker were down 1% in Thursday afternoon trading.The 374.6 million yuan deal, signed with Hangzhou Binjiang Urban Construction Development, covers two parcels of land comprising construction in progress and associated land rights.The parties entered into the agreement on Tuesday, Nov. 11.","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["BK1583","BK1574","CFA.SI","BK1100","02500"],"gpt_icon":0},{"id":"1192830237","title":"HK Stock Movement | GENFLEET-B (02595) Surges Over 8% in Late Trading as GFH375 Tablets Enter Phase III Clinical Trial for Metastatic Pancreatic Cancer","url":"https://stock-news.laohu8.com/highlight/detail?id=1192830237","media":"Stock News","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1192830237?lang=en_us&edition=fundamental","pubTime":"2025-11-13 15:58","pubTimestamp":1763020694,"startTime":"0","endTime":"0","summary":"GENFLEET-B (02595) rose more than 8% in late trading, closing up 7.46% at HK$31.1 with a turnover of HK$28.08 million. On November 11, the drug clinical trial registration platform revealed that...","market":"sg","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK1515","09939","02595","BK1161","BK4134","159938","III","BK1574"],"gpt_icon":0},{"id":"1158005608","title":"Haisco Pharmaceutical (002653.SZ) Receives Approval for New Indication of Innovative Drug HSK39297 Tablets in Clinical Trials","url":"https://stock-news.laohu8.com/highlight/detail?id=1158005608","media":"Stock News","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1158005608?lang=en_us&edition=fundamental","pubTime":"2025-11-13 15:48","pubTimestamp":1763020091,"startTime":"0","endTime":"0","summary":"Haisco Pharmaceutical Group Co., Ltd. (002653.SZ) announced that it recently received the \"Drug Clinical Trial Approval Notice\" from the National Medical Products Administration. After review, the...","market":"sg","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["159992","BK0188","002653","06978","BK1574","BK0033","BK0077","BK0028","BK1161","BK0239"],"gpt_icon":0},{"id":"2583568100","title":"Ascentage Pharma (SEHK:6855): Evaluating Valuation After ASH Meeting Spotlights Pipeline Progress","url":"https://stock-news.laohu8.com/highlight/detail?id=2583568100","media":"Simply Wall St.","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2583568100?lang=en_us&edition=fundamental","pubTime":"2025-11-13 15:38","pubTimestamp":1763019485,"startTime":"0","endTime":"0","summary":"Ascentage Pharma Group International (SEHK:6855) saw attention rise after announcing that new clinical and preclinical results on olverembatinib, lisaftoclax, and APG-5918 will be featured at the 67th ASH Annual Meeting. This recognition for its drug candidates highlights the company’s development programs and keeps them in focus for investors.\nSee our latest analysis for Ascentage Pharma Group International.\nThis spotlight at ASH comes after a year of strong momentum for Ascentage Pharma...","market":"hk","thumbnail":"https://images.simplywall.st/asset/industry/6111000-choice1-main-header/1585186710114","type":0,"news_type":0,"thumbnails":["https://images.simplywall.st/asset/industry/6111000-choice1-main-header/1585186710114"],"rights":{"source":"simplywall_highlight","url":"https://simplywall.st/stocks/hk/pharmaceuticals-biotech/hkg-6855/ascentage-pharma-group-international-shares/news/ascentage-pharma-sehk6855-evaluating-valuation-after-ash-mee","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://simplywall.st/stocks/hk/pharmaceuticals-biotech/hkg-6855/ascentage-pharma-group-international-shares/news/ascentage-pharma-sehk6855-evaluating-valuation-after-ash-mee","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"simplywall_highlight","symbols":["LU2065732104.USD","BK1574","BK4097","BK4109","PRGS","BK1161","ASH","06855","LU2463526074.USD"],"gpt_icon":0},{"id":"1126925116","title":"IPO Preview | Weijian Pharma: Doubling H1 2025 Revenue Ahead of Listing","url":"https://stock-news.laohu8.com/highlight/detail?id=1126925116","media":"Stock News","labels":["preview"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1126925116?lang=en_us&edition=fundamental","pubTime":"2025-11-13 14:46","pubTimestamp":1763016389,"startTime":"0","endTime":"0","summary":"Weijian Pharma, China's leading pharmaceutical company with the largest portfolio of commercialized innovative drugs for kidney diseases, has filed for its Hong Kong IPO. On November 7, the company...","market":"sh","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"preview","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["09939","BK1574","159938","BK1515","BK1161"],"gpt_icon":0}],"pageSize":20,"totalPage":15,"pageCount":1,"totalSize":288,"code":"91000000","status":"200"}]}}